loading page

ABCC2(rs717620), and ABCC3 (rs4793665) affect high dose Methotrexate toxicity, and outcome in children with osteosarcoma
  • +4
  • Amr Yahia,
  • Rania Labib,
  • Sameh A. Abdelshafi3,
  • Asmaa Salama,
  • Omneya Hassanain,
  • Hoda Rabea,
  • Enas Elnadi
Amr Yahia
Pharm D; Faculty of Pharmacy Beni-Suef University, Teaching assistant Clinical Pharmacy (Pharmacy Practice) Department; Faculty of Pharmacy, Horus University- Egypt (HUE)
Author Profile
Rania Labib
Children's Cancer Hospital Egypt 57357
Author Profile
Sameh A. Abdelshafi3
Children's Cancer Hospital Egypt 57357
Author Profile
Asmaa Salama
Children's Cancer Hospital Egypt 57357
Author Profile
Omneya Hassanain
Children's Cancer Hospital Egypt 57357
Author Profile
Hoda Rabea
Beni Suef University Faculty of Pharmacy
Author Profile
Enas Elnadi
Children's Cancer Hospital Egypt 57357
Author Profile

Abstract

Objectives: Osteosarcoma (OS) is one of the aggressive bone tumors commonly diagnosed in adolescents and young adults. The study investigated the effect of 9 single nucleotide polymorphisms (SNPs) in 5 genes on methotrexate (MTX) plasma level and its impact on the patients’ clinical outcomes. Methods: One hundred and thirty-three patients with OS (68 boys and 65 girls with age range 4.00-17.86 years) were enrolled and treated with four weeks of high-dose methotrexate (HDMTX) as neo-adjuvant therapy in children’s cancer hospital (CCHE-57357). Blood samples were collected and genotyped for the studied SNPs (MTHFR rs1801133, SLCO1B1 rs11045879, rs4149081, rs2306283, ABCC3 rs4793665, rs4148412, rs733392 ABCG2 rs2231142, and ABCC2 rs717620 using Taqman® (RT-PCR) assay. Plasma concentrations of MTX were measured using the enzyme multiple immunoassay technique (EMIT®). The clinical outcomes included toxicities that were evaluated based on the common terminology criteria for adverse events - version 5 (CTCAEv5.0.), besides the studying of survival analysis and tumor necrosis (TN %). Results: Older patients experienced increased risk of delayed MTX elimination at 72-hour, OR=1.19 (95% CI=1.09-1.29, p=0.00059). The studied SNPs weren’t associated with MTX elimination. Patients with ABCC2 HW (Homozygous wild) genotype group showed a high statistically significant association with higher grade hyperbilirubinemia, OR= 2.05(95% CI=1.05-4.01, p=0.037). Moreover, the patients with ABCC3 (rs4793665) HV and HT (Homozygous variant and Heterozygous) genotypes had a significant association with severe nephrotoxicity, OR= 0.34(95% CI=1.6-0.72, p=0.005). Conclusions: ABCC2 (rs717620), ABCC3 (rs4793665) genotyping with age and gender could help in predicting patients at risk of toxicities due to HDMTX.